Metastatik kolorektal kanser hastalarında 3. basamak tedavi seçeneği:  rechallenge kemoterapi

Ersin Özaslan; Oktay BOZKURT; Ayşe Ocak Duran; Mevlude İnanç; Metin Özkan

Article Details

Metastatik kolorektal kanser hastalarında 3. basamak tedavi seçeneği: rechallenge kemoterapi

Authors:

Ersin Özaslan | Oktay BOZKURT | Ayşe Ocak Duran | Mevlude İnanç | Metin Özkan

Publisher:

MEDİTAGEM Ltd. Şti.

Main Topics:

Promotion of health

Journal:

Ortadogu Medical Journal 2017 Vol.9 Issue 4, pp.163-169

Document Type:

Article

Publication Date:

11/2017

Document Language:

Turkish

Document ID (Org No.):

2000768544

Frequency:

Quarterly

eISSN:

2548-0251

Keywords:

Abstract:

 


Objective: Currently, there is required effective option in third line therapy after irinotecan and oxaliplatin based regimen because of survival of metastatic colorectal carcinoma (mCRC) increase. A repeated chemotherapy regimen (rechallenge therapy) may be an option in selective patients.


Patients and Methods: Patients were rechallenged with irinotecan or oxaliplatin regimen as a third line therapy which was the same therapy that they received as the first line. Response Evaluation Criteria in Solid Tumors (RECIST) was used to retrospectively calculate tumor response and Kaplan Meier method to calculate survival.


Results: Forty-five patients were found to be eligible for this study. The median follow up duration was 29 months. Thirty-three patients (73%) had been lost during follow up. Of the rechallenge treatments, 23 (51%) patients were administered irinotecan and 22 (49%) oxaliplatin based regimens. Most patients had a good performans status as 0 or 1 and K-RAS wild-type was detected in 31 (69%) of the patients. The common toxicities were haematologic and gastrointestinal, mostly grade 1 and 2. Response rate was 8.9%, while 25 (55.5%) of the patients had stable disease. Clinical benefit rate was calculated as 64.4%. The median progression-free survival (PFS) as 6 months (95% CI: 4.68–9.55 months) and the median overall survival (OS) was found as 10 months (95% CI: 7.00–12.99 months).


Conclusions: The results of this study indicate that rechallenge treatment may be a right choice as a third line therapy for selected patients.



.

Article Details

Metastatik kolorektal kanser hastalarında 3. basamak tedavi seçeneği: rechallenge kemoterapi

Authors:

Ersin Özaslan | Oktay BOZKURT | Ayşe Ocak Duran | Mevlude İnanç | Metin Özkan

Publisher:

MEDİTAGEM Ltd. Şti.

Main Topics:

Promotion of health

Journal:

Ortadogu Medical Journal 2017 Vol.9 Issue 4, pp.163-169

Document Type:

Article

Publication Date:

11/2017

Document Language:

Turkish

Document ID (Org No.):

2000768544

Frequency:

Quarterly

eISSN:

2548-0251

metastatic colorectal carcinoma

rechallenge chemotherapy

third line

salvage

Issues

Article Details

Metastatik kolorektal kanser hastalarında 3. basamak tedavi seçeneği: rechallenge kemoterapi

Authors: Ersin Özaslan | Oktay BOZKURT | Ayşe Ocak Duran | Mevlude İnanç | Metin Özkan

Publisher: MEDİTAGEM Ltd. Şti.

Main Topics: Promotion of health

Journal: Ortadogu Medical Journal 2017 Vol.9 Issue 4, pp.163-169

Document Type: Article

Publication Date: 11/2017

Document Language: Turkish

Document ID (Org No.): 2000768544

Frequency: Quarterly

eISSN: 2548-0251

metastatic colorectal carcinoma

rechallenge chemotherapy

third line

salvage

Issues

Authors:

Ersin Özaslan | Oktay BOZKURT | Ayşe Ocak Duran | Mevlude İnanç | Metin Özkan

Publisher:

MEDİTAGEM Ltd. Şti.

Main Topics:

Promotion of health

Journal:

Ortadogu Medical Journal 2017 Vol.9 Issue 4, pp.163-169

Document Type:

Article

Publication Date:

11/2017

Document Language:

Turkish

Document ID (Org No.):

2000768544

Frequency:

Quarterly

eISSN:

2548-0251